We are seeking to connect and collaborate with like-minded people and organisations wanting to make an impact through:
Partner With Us
One Australian dies from melanoma every six hours. Your organisation’s contribution will enable more melanoma patients to access potentially life-saving treatments, services, and support.
- Co-branded/partnership opportunities
- In-kind support
- Promotional support
- Regular giving
We’re on a mission to beat melanoma, for good. Will you join us?
4 ways organisations can support NEMF
Co-branded partnership opportunities
Partner with us to create meaningful, high-impact campaigns to raise awareness and funds for melanoma patients.
In-kind Support
Donate products, services, or expertise to help us run events, reach more people, and raise more money to help more patients.
Promotional Support
Use your platform/s to spotlight our cause and help amplify our awareness-raising message to your community.
Regular Giving
Join our circle of committed partners making an ongoing impact in the lives of Australians receiving treatment for late-stage melanoma.
”Sadly, Neil lost his battle [with melanoma] in June 2021. In his final days he spoke of his desire to set up a foundation to enable people with less financial means than himself to have access to the latest treatment options. Today, our Patient Fund is helping others have a fighting chance to beat their melanoma!
Sonia NazaretianFounder, Neil Evans Melanoma Foundation
”Although the drugs may not have worked in him, Neil was hopeful that someone down the track in his position may actually benefit. At MIA, our mission is a simple one – zero deaths from melanoma. The Neil Evans Melanoma Foundation will be an important part of this journey.
Professor Georgina Long, AOCo-Medical Director, Melanoma Institute Australia
”I became a recluse and I felt totally incapacitated. I just wanted it all to stop.
Martina DuleskaWollongong, NSW
Thanks to the support of the Neil Evans Melanoma Foundation, 21-year-old Martina Duleska’s life was turned around with access to a non-PBS drug to manage a severe side effect from her treatment for Stage III melanoma.
